Tags: Drug.
Denileukin diftitox (trade name Ontak) is an antineoplastic agent an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors so denileukin diftitox can target these. In 1999 Ontak was approved by the U.S.